Canada markets closed

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.4100-0.0800 (-3.21%)
At close: 1:00PM EST
2.4100 0.00 (0.00%)
After hours: 02:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.4900
Bid2.3800 x 900
Ask3.1900 x 1100
Day's Range2.2450 - 2.4500
52 Week Range1.8100 - 6.5700
Avg. Volume432,719
Market Cap222.278M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-0.4170
Earnings DateNov. 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.40
  • Simply Wall St.

    Is OncoCyte (NASDAQ:OCX) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other biomarkers DetermaIO data in Triple Negative Breast Cancer published in a peer reviewed journal and confirmed in a randomized clinical trial study presented at ESMO; Evidence in fourth tumor type suggests pan-cancer utility DetermaRx test volume grows 65% year over year US transplant IP issued supp

  • GlobeNewswire

    Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test

    DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has consistently proven to be more precise at identifying patients who are immunotherapy responders including those who may have been missed by PDL-1 IHC and other biomarkers IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with th